Gambrell R D, Massey F M, Castaneda T A, Ugenas A J, Ricci C A, Wright J M
Obstet Gynecol. 1980 Jun;55(6):732-8.
In contrast to several retrospective studies reporting an increased risk of endometrial cancer during the mid-1970s, especially in estrogens.gen-treated postmenopausal women, the number of cancers at Wilford Hall USAF Medical Center has steadily declined despite continued estrogen use. In a 4-year study from 1975 to 1978, there were 17 adenocarcinomas of the endometrium during 10,872 patient-years of observation, for an overall annual incidence of 156.4:100,000 women. The highest incidence of endometrial cancer (359.1:100,000) was found in those women using estrogens alone. The lowest incidence of cancer was observed in the estrogen-progestogen users (56.4:100,000) and was significantly lower (P less than .01) than that found in the estrogen users. The incidence of corpus malignancy in the estrogen-progestogen users was also significantly lower (P less than .05) than that observed in the untreated women (248.3:1000,000). The progestogen challenge test has been devised to identify postmenopausal women at greatest risk for adenocarcinoma of the endometrium. It is concluded that the use of this test will reduce the risk of endometrial cancer in both estrogen-treated postmenopausal women and women with increased endogenous estrogens.
与几项回顾性研究报告的20世纪70年代中期子宫内膜癌风险增加的情况相反，尤其是在接受雌激素治疗的绝经后女性中，尽管持续使用雌激素，但美国空军威尔福德霍尔医疗中心的癌症病例数却在稳步下降。在1975年至1978年的一项为期4年的研究中，在10872患者年的观察期内有17例子宫内膜腺癌，总体年发病率为156.4:100000名女性。子宫内膜癌发病率最高的是那些仅使用雌激素的女性（359.1:100000）。在使用雌激素 - 孕激素的女性中观察到的癌症发病率最低（56.4:100000），且显著低于雌激素使用者（P小于0.01）。雌激素 - 孕激素使用者的子宫恶性肿瘤发病率也显著低于未治疗女性（248.3:100000）（P小于0.05）。孕激素激发试验已被设计用于识别子宫内膜腺癌风险最高的绝经后女性。得出的结论是，使用该试验将降低接受雌激素治疗的绝经后女性和内源性雌激素增加的女性患子宫内膜癌的风险。
